Reports Q1 revenue $896M, consensus $901.1M. “We made tangible progress in the first quarter as we continue to integrate Merus and advance our late-stage portfolio – EPKINLY, Rina-S and petosemtamab. Across the business, our focus remained on disciplined execution, progressing these programs toward key readouts and preparing for potential launches to have an impact on more patients,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab (GMAB).
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab Advances Rina S Into Phase 2 GI Cancer Trial, Raising Long Term Pipeline Hopes
- Genmab Posts Strong Q1 2026 Revenue Growth and Highlights FDA Label Change for EPKINLY
- Genmab price target lowered to $38 from $40 at H.C. Wainwright
- Genmab: Buy Rating Backed by Expanded Petosemtamab-Keytruda Phase III Trial and Blockbuster Late-Stage Pipeline
- Genmab upgraded to Outperform from Neutral at BNP Paribas